Document text
Principal Investigator: Caleb Andrew Lareau
Organization: SLOAN-KETTERING INST CAN RESEARCH
Fiscal Year: 2024
Award: $1,061,833
Funding agency: National Center for Complementary and Integrative Health
PROJECT SUMMARY
At the turn of the millennium, the cost of sequencing one megabase of DNA exceeded 10 million
dollars. Today, decoding that same megabase costs less than a penny. This dramatic reduction in the cost of
sequencing has catalyzed a genomics revolution and resulted in petabases (millions of billions of bases) of
DNA and RNA- sequences from human cells and tissues. We hypothesize that this transformational capacity of
next-generation sequencing will now catalyze our understanding of the human virome—both by illuminating the
set of DNA viruses in human tissues and by profiling the host (human) cells that are infected.
Here, we outline new computational and experimental methods to realize the unique potential of
petabase-scale sequencing data in studying human DNA viruses. Our work will uncover foundational aspects
of the human virome, including tissue tropism and cellular reservoirs for all DNA viruses. Further, we present
complementary strategies through host genetics analyses and single-cell multi-omics to define and
characterize the molecular interactions of human cells associated with viral infections and latency.
First, in Aim 1, we will develop methods to quantify latent viral features from petabases of unmapped
whole genome sequencing reads from hundreds of thousands of individuals. These new molecular variables
will reveal the degree of latent viral DNA in blood and will be paired with comprehensive host genotyping and
phenotyping. We will determine host genetics factors associated with high viral levels and nominate
phenotypes, including complex disease, that may be driven by long-term latent infection in individuals.
In Aim 2, we will extend our petabase-scale resource (Serratus) to create a ‘Digital Human Virome’ by
uniformly processing billions of dollars of public sequencing data from human cells and tissues to identify and
quantify all DNA viruses. Our resource will aggregate meta-data to extract sex, cell/tissue of origin, disease
status, and geographic location to create a Digital Human Virome for DNA viruses, revealing tissue tropism
that can be mined for clinical associations, such as our recent discovery of HHV-6 reactivation in CAR T cells.
Finally, in Aim 3, we will develop a new high-throughput single-cell multi-omics technology termed
‘Latent-seq’ that will identify individual human cells that harbor latent viruses with paired high-quality cell state
measurements. We will first establish and benchmark the assay using a set of well-defined cell lines before
extending applications to primary human tissues in collaboration with the Human Virome Program Consortium.
Together, these workflows will define human DNA virome in health and disease by leveraging this
unique moment in the capacity of genomics technologies. As every human gets infected by endemic eukaryotic
DNA viruses, but only some individuals ever show symptoms, our systematic approaches will uncover new
associations between molecular interactions and human phenotypes intertwined with the human virome.
Terms: <65 and older><65 or older><65 years of age and older><65 years of age or more><65 years of age or older><65+ years><65+ years old><> 65 years><Acceleration><Acute><Address><Aged 65 and Over><Assay><Attenuated><Benchmarking><Best Practice Analysis><Binding><Bioassay><Biological Assay><Biology><Blood><Blood Reticuloendothelial System><Body Tissues><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><Cell Body><Cell Line><CellLine><Cells><Clinical><Collaborations><Complex><Computing Methodologies><Coupled><DNA><DNA Sequence><DNA Virus Infections><DNA Viruses><DNA mapping><DNA seq><DNA sequencing><DNA viral infections><DNAseq><Data><Data Science><Data Set><Deoxyribonucleic Acid><Development><Disease><Disorder><Gene variant><Genetic><Genetic Diversity><Genetic Variation><Genetic analyses><Genomics><Genotype><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><HBLV><HHV-6><HHV6><Health><Host Factor><Host Factor Protein><Human><Human B-Lymphotropic Virus><Human Herpesvirus 6><Immune system><Individual><Infection><Integration Host Factors><Lead><Life><Link><Maps><Measurement><Measures><Metadata><Methodology><Methods><Modern Man><Molecular><Molecular Interaction><NGS Method><NGS system><Pathway interactions><Pb element><Phenotype><Population><Property><RNA Sequences><Research Resources><Resolution><Resources><Sampling><Sequence Read Archive><Short Read Archive><Strains Cell Lines><Symptoms><T cells for CAR><Technology><Tissues><Tropism><Variant><Variation><Viral><Viral Diseases><Viral Latency><Viral reservoir><Virus><Virus Diseases><Virus Latency><Virus reservoir><Virus-HHV6><Work><above age 65><after age 65><age 65 and greater><age 65 and older><age 65 or older><age > 65><age of 65 years onward><aged 65 and greater><aged 65+><aged ≥65><allele variant><allelic variant><attenuate><attenuates><base><bases><benchmark><bio-informatics tool><biobank><bioinformatics tool><biorepository><cell type><chemotherapy><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cofactor><cohort><computational methodology><computational methods><computer based method><computer methods><computing method><cost><cultured cell line><developmental><digital><entire genome><full genome><genetic analysis><genetic strain><genetic variant><genome sequencing><genomic tools><genomic variant><geographic site><global gene expression><global transcription profile><heavy metal Pb><heavy metal lead><human DNA><human RNA sequencing><human RNA-seq><human data><human disease><human old age (65+)><human tissue><human virome><infancy><infantile><latency/reactivation><latent infection><meta data><multiomics><multiple omics><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next gen sequencing><next generation sequencing><next generation therapeutics><nextgen sequencing><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><old age><over 65 years><panomics><pathogen><pathway><programs><reactivation from latency><resolutions><seropositive><sex><single cell genomics><stable cell line><tech development><technological innovation><technology development><tissue tropism><trait><transcriptome><viral DNA><viral infection><viral microbiome><virome><virus DNA><virus infection><virus-induced disease><whole genome><≥65 years>